Next Article in Journal
Cartilage Regeneration Using Human Umbilical Cord Blood Derived Mesenchymal Stem Cells: A Systematic Review and Meta-Analysis
Next Article in Special Issue
Identification of Genomic Variants of SARS-CoV-2 Using Nanopore Sequencing
Previous Article in Journal
Changes in Trunk Muscle Activity during Unilateral Weight Bearing and Abnormal Postural Gait in Healthy Individuals
Previous Article in Special Issue
Effect of the Duration of NSAID Use on COVID-19
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicina
Volume 58
Issue 12
10.3390/medicina58121799
medicina-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Surveillance of Side Effects after Two Doses of COVID-19 Vaccines among Patients with Comorbid Conditions: A Sub-Cohort Analysis from Saudi Arabia

by
Tauqeer Hussain Mallhi
1,2,*,
Yusra Habib Khan
1,*,
Muhammad Hammad Butt
3,
Muhammad Salman
4,
Nida Tanveer
5,
Nasser Hadal Alotaibi
1,
Abdulaziz Ibrahim Alzarea
1 and
Abdullah Salah Alanazi
1,2
1
Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka 72388, Saudi Arabia
2
Health Sciences Research Unit, Jouf University, Sakaka 72388, Saudi Arabia
3
Department of Medicinal Chemistry, Faculty of Pharmacy, Uppsala University, 75123 Uppsala, Sweden
4
Institute of Pharmacy, Faculty of Pharmaceutical and Allied Health Sciences, Lahore College for Women University, Lahore 54000, Pakistan
5
Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40202, USA
*
Authors to whom correspondence should be addressed.
Medicina 2022, 58(12), 1799; https://doi.org/10.3390/medicina58121799
Submission received: 31 October 2022 / Revised: 25 November 2022 / Accepted: 25 November 2022 / Published: 6 December 2022
(This article belongs to the Special Issue Advances in Infectious Diseases and Clinical Microbiology during the COVID-19 Pandemic)
Versions Notes

Abstract

:
Background: Individuals with underlying chronic illnesses have demonstrated considerable hesitancy towards COVID-19 vaccines. These concerns are primarily attributed to their concerns over the safety profile. Real-world data on the safety profile among COVID-19 vaccinees with comorbid conditions are scarce. This study aimed to ascertain the side-effects profile after two doses of COVID-19 vaccines among chronic-disease patients. Methodology: A cross-sectional questionnaire-based study was conducted among faculty members with comorbid conditions at a public educational institute in Saudi Arabia. A 20-item questionnaire recorded the demographics and side effects after the two doses of COVID-19 vaccines. The frequency of side effects was recorded following each dose of vaccine, and the association of the side-effects score with the demographics was ascertained through appropriate statistics. Results: A total of 204 patients with at least one comorbid condition were included in this study. A total of 24 side effects were reported after the first dose and 22 after second dose of the COVID-19 vaccine. The incidence of at least one side effect was 88.7% and 95.1% after the first and second doses of the vaccine, respectively. The frequent side effects after the first dose were pain at the injection site (63.2%), fatigue (58.8%), fever (47.5%), muscle and joint pain (38.7%), and headache (36.3%). However, pain at the injection site (71.1%), muscle and joint pain (62.7%), headache (49.5%), fever (45.6%), and stress (33.3%) were frequent after the second dose. The average side-effects score was 4.41 ± 4.18 (median: 3, IQR: 1, 6) and 4.79 ± 3.54 (median 4, IQR: 2, 6) after the first and second dose, respectively. Female gender, diabetes mellitus, hypertension, hyperlipidemia, comorbidity > 2, family history of COVID-19, and the AstraZeneca vaccine were significantly associated with higher side-effect scores. Only 35.8% of study participants were satisfied with the safety of COVID-19 vaccines. Conclusions: Our analysis showed a high proportion of transient and short-lived side effects of Pfizer and AstraZeneca vaccines among individuals with chronic illnesses. However, the side-effects profile was comparable with the safety reports of phase 3 clinical trials of these vaccines. The frequency of side effects was found to be associated with certain demographics, necessitating the need for further investigations to establish a causal relationship. The current study’s findings will help instill confidence in the COVID-19 vaccines among people living with chronic conditions, overcome vaccine hesitancy, and increase vaccine coverage in this population.

1. Introduction

The first case of coronavirus disease (COVID-19) was identified in December 2019 in Wuhan, China. The mortality rate of COVID-19 is lower than that of other coronaviruses such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). However, its causative pathogen, “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)” is considered more contagious than other coronaviruses causing SARS and MERS [1]. Initially, patients with COVID-19 presented with typical manifestations such as fever, fatigue, and respiratory symptoms. However, the rapid distribution of COVID-19 across the globe resulted in several atypical intricacies in various organ systems during the disease course of COVID-19 [2]. Immediate prevention and control measures were taken to curtail the epidemic across the globe. The phenomena of social distancing [3], drug repurposing for the management of patients [4], and the development of vaccines proved to be effective maneuvers to combat the growing encumbrance of COVID-19.
The COVID-19 vaccination is one of the effective preventive measures to curb the encumbrance of the ongoing pandemic [5]. Various health authorities around the globe have endorsed herd immunity as a potential tool against the COVID-19 outbreak. Vaccination against COVID-19 is an essential driver of herd immunity. Despite aggressive and continuous maneuvers to increase vaccine coverage, vaccine hesitancy is still a prominent phenomenon that may impact the process of mass immunization against COVID-19. However, the fear of side effects of the COVID-19 vaccines is considered a dominant factor in vaccine hesitancy [6,7]. The safety of COVID-19 vaccines is of great public health concern and is crucial to neutralize vaccine hesitancy. There has been widespread speculations of serious post-vaccination adverse events. In addition, the safety of these vaccines became a priority concern immediately after a few reports of blood clotting [8], Bell‘s palsy [9], and myocarditis [10] following the administration of specific vaccines.
Healthcare researchers around the globe responded swiftly to the safety profile of the COVID-19 vaccines and conducted various post-marketing real-world surveillance studies of side effects among vaccinees [11,12,13,14]. However, there is a dearth of investigations into post-vaccination side-effects of COVID-19 vaccines among recipients with underlying comorbid conditions. In addition, there are also increased safety concerns regarding the vaccination of people living with underlying chronic conditions [15]. The use of more than one medication and the co-occurrence of multiple health conditions among chronic-disease patients may increase the frequency and severity of the post-vaccination side effects [15,16]. It is pertinent to mention that most of the clinical trials on vaccines have included only stable chronic-disease patients. Moreover, this population accounted for only 15% to 42% of total participants in these trials [17]. Most chronic-disease patients remain reluctant to adopt any therapeutic intervention except the medications they are already receiving. Yi et al. reported that most of the patients with rheumatic diseases were reluctant to receive COVID-19 vaccines due to the fear of side effects and disease flare [18]. These findings are alarming, as patients with rheumatic diseases are at high risk of COVID-19 infection attributed to their compromised immune systems [19]. However, recent investigations have demonstrated satisfactory immunogenicity and an acceptable safety profile of the COVID-19 vaccines among patients with autoimmune inflammatory rheumatic diseases (AIIRDs) [20,21]. The findings of Li et al. also encourage COVID-19 vaccination among rheumatic-disease patients. The authors have reported a satisfactory safety profile of COVID-19 vaccines among individuals with various rheumatic diseases, and indicated that immunosuppressive therapy was not associated with the frequency of side effects [21]. Educating these patients regarding the benefits and safety of COVID-19 vaccines will ensure optimal coverage. Similar results have also been observed in a study conducted on the Saudi population, where adults with chronic conditions demonstrated a low willingness to receive the COVID-19 vaccination [22]. It is expected that people with chronic health conditions will hesitate to receive COVID-19 vaccines, most probably due to fear of side effects. In this context, there is an impetus to inform this population regarding safety profile of the COVID-19 vaccines. Cautious pharmacovigilance is indeed warranted for people with one or more chronic illnesses. This study aimed to ascertain the prevalence of side effects after the first and second doses of COVID-19 vaccines among chronic-disease patients. Moreover, this study determined the relationship between the frequency of side effects and the demographics. The findings may serve to inform the general community regarding the safety of COVID-19 vaccines among individuals with underlying medical conditions.

2. Materials and Methods

2.1. Ethics Statement

The study protocol was approved by the Local Committee of Bioethics (LCBE) at Jouf University, KSA (Reference: 05-05-43). Informed consent was obtained from all the participants and data were anonymized before analysis.

2.2. Study Design, Population, and Location

This study is a sub-cohort analysis of an ongoing project on the pharmacovigilance of the COVID-19 vaccines. This project aimed to collect data on the side effects of COVID-19 vaccines from university students, faculty members, and the general population. Since the side-effects profile of COVID-19 vaccines among chronic-disease patients is lacking in the literature, a sub-group analysis on vaccinees with chronic disease was performed. Considering the dire need for a rapid report on the safety profile of the COVID-19 vaccines among chronic-disease patients, data on faculty members of Jouf University, Saudi Arabia were readily available for analysis. The participants who had received at least two doses of the COVID-19 vaccines, had at least one chronic condition, and consented to participate were included in this study, or otherwise excluded.

2.3. Validation and Reliability of Study Instrument

A 20-item questionnaire comprising three sections was constructed by a team of physicians and hospital/community pharmacists. Following the face and content validity, the study instrument was administered to a small sample of 30 participants. The internal consistency of the study tool was estimated through Cronbach‘s alpha at 0.821, indicating the suitability and reliability of the study instrument.

2.4. Components of Study Instrument

The study instrument was specifically designed to evaluate the safety profile of COVID-19 vaccines. The questionnaire was initially designed in English. The English version was translated into Arabic with the help of native Arabic speakers using forward–backward translation. The study questionnaire consisted of four sections. Section 1 collected information on demographics including age, gender, marital status, nationality, and education. Section 2 inquired about the chronic conditions present among the study participants. Section 3 evaluated the safety profile of vaccines such as the type of side effect after each dose of vaccine, the onset and duration of side effects, and their management. Section 4 had two questions inquiring about the satisfaction and recommendation of the COVID-19 vaccines among study participants. The list of side effects included all common events reported in clinical trials of vaccines as well as in the previous literature. Moreover, participants were also encouraged to document any other side effect that was not present in the list. All the participants were asked to respond against each side effect on a scale of “Yes” and “No”. The option “Yes” was scored “1”, otherwise “zero”. A cumulative side-effect score of each participant was estimated by adding the total number of side effects. The mean side-effects scores were also estimated after the first and second doses of COVID-19 vaccines. The total number of side effects after the first and second dose was estimated. This resulted in a cumulative side-effect score (CSES) (the presence of each side effect was scored 1). The average side-effect score (ASES) was also estimated after each dose (ASES = (CSES-Dose 1 + CSES-Dose 2)/2). The reported side effects were further stratified into four categories i.e., common (side effects indicated by >50% of the study population), moderately common (30–50%), uncommon (10% to <30%), and rare (<10%). The respondents were also asked to rate the severity of side effects from mild to moderate or severe.

2.5. Data Collection

Using a convenient sampling technique, the questionnaire was distributed among the staff of the Jouf University via official emails with regular reminders at predefined intervals. A brief overview of the study was given to the participants. Subsequently, the participants were asked about their volunteer participation in this study and an online consent was obtained with the statement “I agree to participate in this study”. If the participants did not agree, the form was submitted without recording their responses. All questionnaires were checked for completeness and transferred to a Microsoft spreadsheet for cleaning purposes. Initially, all the data were collected but only responses meeting the inclusion criteria were included in the analysis.

2.6. Statistical Analysis

All the data were subjected to analysis by Statistical Package for Social Sciences (IBM-SPSS version 25). The data were descriptively presented as the frequency with proportion and mean with standard deviation. The categorical data were compared with the Chi-square test i.e., the comparison of side effects across demographics and types of the COVID-19 vaccine. The independent Student’s t-test and one-way ANOVA compared the mean score between two or more than two groups, respectively. Pearson correlation was used to estimate the relationship between the number of side effects and comorbidities. The coefficient of determination was also estimated through linear regression. A significance level of p < 0.05 value was adjusted in all analyses.

3. Results

3.1. Demographics

A total of 204 patients with at least one comorbid condition were included in the analysis. The age of the participants ranged from 30 to 49 years. The most common comorbid condition was diabetes mellitus (41.2%) followed by hypertension (31.9%) and hyperlipidemia (30.4%). Almost a quarter of the participants (23.5%) had a history of COVID-19 infection. Most of the participants (62.3%) had received two doses of Pfizer vaccine (BioNTech, BNT162b2), and only 17.2% had received two doses of Astra-Zeneca (Oxford, AZD1222). A homologous vaccine regime was used in 79.9% of participants, while 20.1% of participants received a heterologous regime. The post-vaccination COVID-19 infection rate was only 2% in this study (Table 1).

3.2. Incidence of Side Effects after COVID-19 Vaccines

The incidence of at least one side effect was 88.7% and 95.1% after the first and second doses of the vaccine, respectively. Pain at the injection site and fatigue were common side effects after the first dose, while pain at the injection site and muscle or joint pain were common side effects after the second dose. The frequent side effects after the first dose were pain at the injection site (63.2%), fatigue (58.8%), fever (47.5%), muscle and joint pain (38.7%), and headache (36.3%). However, pain at the injection site (71.1%), muscle and joint pain (62.7%), headache (49.5%), fever (45.6%), and stress (33.3%) were frequent after the second dose. Most of these side effects occurred within the 6 h following the first dose (45.1%) and second dose (28.4%). Most of the side effects (61.3%) lasted for 48 h among the study participants (Table 2).

3.3. Side-Effect Score and its Association with Demographics

A total of 24 side effects were reported after the 1st dose, and 22 after the 2nd dose of the COVID-19 vaccines. The average -effects score was 4.41 ± 4.18 (median: 3, IQR: 1, 6) and 4.79 ± 3.54 (median 4, IQR: 2, 6) after the first and second dose, respectively. However, the cumulative side-effect score after both doses was 4.60 ± 2.93 (median: 4.2, IQR: 2.5, 6.5). The number of comorbidities was found to be positively correlated with side-effects score after the first dose (r = 0.345, R2 = 0.125, p < 0.001), second dose (r = 0.230, R2 = 0.053, p < 0.001), and both doses (r = 0.390, R2 = 0.152, p < 0.001). Female gender, diabetes mellitus, hypertension, hyperlipidemia, comorbidity count more than 2, family history of COVID-19 infection, and the Astra-Zeneca vaccine were significantly associated with higher side-effect scores following the first dose. On the other hand, participants aged 30–49 years, >2 comorbidities, family history of COVID-19 infection, and those who received Pfizer had significantly higher side-effect scores after the second dose (Table 3). It is pertinent to mention that homologous and heterologous vaccine regimes were not associated with the SES (score: 4.83 versus 4.61, p = 0.717) (Table 3). Table 4 and Table 5 show that the occurrence of certain side effects (common and moderately common) was statistically associated with various demographic features.

3.4. Self-Reported Side Effects Severity and Medication Recommendations

Around 7% of participants reported that the side effects were severe after both doses, while 4.4% and 6.9% indicated the severe nature of side effects after the first and second doses, respectively. Paracetamol was recommended to 44.1% of study participants. However, vitamin C along with paracetamol was recommended in 5.4% of vaccine recipients. Medical consultation was sought by 5.4% of vaccinees due to severe side effects, and such consultation was more frequent after the first dose (3.4%). Only 2% of participants reported healthcare consultation after both doses.

3.5. Perception of Respondents towards Safety of Vaccination

Only 35.8% of vaccinated individuals considered the COVID-19 vaccines safe, while 9.3% suggested that they are not safe and 54.9% were not sure about their safety. However, three-fourths (75.5%) of the study population indicated that they recommend vaccines to their family members and friends.

4. Discussion

To the best of our knowledge, this is the first study to assess the side-effects profile following two doses of COVID-19 vaccines among individuals with comorbid illnesses in the Northern Region of Saudi Arabia. Given the rapid development of COVID-19 vaccines, the safety and efficacy of these vaccines remain an area of concern [23]. Such concerns are even more profound for patients with comorbid conditions due to the high prevalence of polypharmacy and vaccine hesitancy in this population [15,16,17,22]. Our analysis showed that the safety profile of COVID-19 vaccines among chronic-disease patients is comparable to healthy individuals, and these findings are aligned with the existing claims [24,25]. However, the incidence of at least one side effect was higher in individuals with comorbidities when compared to those without any underlying medical conditions. This result is aligned with the findings of Alemayehu et al. where authors reported that the magnitude of COVID-19 vaccine adverse effects was comparatively higher among participants with comorbid conditions [26]. Considering the higher risks of disease progression or death during COVID-19, the benefits of the COVID-19 vaccination outweigh the risks among patients with underline medical conditions.
Various clinical trials on vaccine development have included 20% to 30% of individuals with underlying medical conditions. The trials on Pfizer [27] and Moderna [28] vaccines showed that the protective effects were similar across the study participants with and without comorbidities [25]. However, the trials on Astra-Zeneca [29,30] and Janssen [31] showed better protective effects among participants without any comorbid condition than those with comorbidities, but the difference was statistically insignificant. It is important to note that mortality was not associated with any vaccine among participants with and without comorbid conditions. Based on these results, The Advisory Committee on Immunization Practices (ACIP) in the USA, The Joint Committee on Vaccination and immunization (JCVI) in the UK, and the WHO Strategic Advisory Group of Experts on Immunization (SAGE) recommend the vaccination for individuals with high-risk comorbidities [25].
Most of the participants in our study experienced at least one side effect following both doses of COVID-19 vaccines. These findings are in concordance with the results of a large surveillance report from the United Arab Emirates (UAE), where participants with comorbidities experienced more side effects than those without any comorbid condition [32]. Other studies among Arab population have also demonstrated significant association of chronic diseases with the development [33], as well as frequency and severity, of postvaccination side effects [34]. However, another study of Turkish healthcare workers revealed no association of chronic illness with the emergence and intensity of side effects following the Sinovac vaccine [35]. This inconsistency in results might be attributed to the differences in the study population and type of vaccines. Moreover, the existing evidence suggests a lower frequency of side effects after Sinovac than the Pfizer and Astra-Zeneca vaccines. Elnaem et al. reported that the frequency of side effects among recipients of the Sinovac vaccine was significantly lower than Pfizer-BioNTech and Oxford-Astra-Zeneca recipients [36]. This might be a contributing factor to a high prevalence of side effects, as all the participants in our study received either Pfizer or Astra-Zeneca vaccines. These findings suggest the relationship between the type of vaccine and the frequency of side effects. He et al. reviewed the comparative efficacy and safety of various COVID-19 vaccines and reported a high prevalence of local and systemic side effects after mRNA (Pfizer) and adenovirus-based (Astra-Zeneca) vaccines [37], and these results are aligned with our findings. Interestingly, the frequency of side effects was slightly higher after the second dose and these findings are in agreement with other investigations [38,39,40]. However, these findings are contradicted by the results of some other studies [41,42] where the proportion of side effects was more profound after the first dose. It is pertinent to mention that these contradictions might be attributed to the variation in the study population, the types of vaccines, and the status of chronic illnesses among participants. Taken together, our analysis confirms the high proportion of side effects among Pfizer and Astra-Zeneca recipients with chronic diseases, particularly in those with diabetes mellitus, hypertension, and hyperlipidemia. Moreover, the frequency of side effects was more among patients with >2 comorbid conditions. These results necessitate the need for more investigations on the correlation of type and number of comorbidities with the safety profile of the COVID-19 vaccines.
The distribution of side effects was similar to that reported in other studies [24,43], where the most commonly reported complaints were pain at the injection site, headache, muscle/joint pain, and fever. Most of these symptoms were reported within 6 h following the jab. The recipients of Astra-Zeneca experienced more side effects as compared to Pfizer vaccinees. Likewise, the participants who received two doses of Pfizer had an average of four side effects while recipients of two doses of Astra-Zeneca had an average of six side effects). These findings corroborate the results of other studies [24,43,44] comparing the frequencies of side effects across the types of vaccines. However, it is important to note that a conclusion on the association of the frequency of side effects with the type of vaccine should not be established, as this such association is markedly affected by the recipient‘s demographics. A recent meta-analysis has indicated a higher incidence of side effects following the administration of the Sputnik vaccine [45]. Since these side effects are self-reported by the vaccinees, several covariates must also be considered while interpreting the results. Considering the relationship of demographics with side-effects score, only gender and age were associated with the incidence of side effects after the first and second dose, respectively. Our analysis showed a higher frequency of side effects among females after the first dose as compared to males. These results are in contrast with the findings of Al Bahrani et al. [46] but in agreement with other investigations [24,47]. The higher frequency of side effects among females is well explained by biological mechanisms such as stronger antibody, innate, and adaptive immune responses among females [48]. It is pertinent to mention that the side-effects score was higher among males after the second dose, but the difference was not significant. Similar to other studies [24], our analysis showed that the side effects were more common among the adult population. These results indicate that the pattern of side effects reported among individuals with chronic conditions was similar to that reported among the healthy population.
In this study, 7% of the study population reported that the side effects were severe after both doses, while 6.9% reported more severe side effects after the second dose. Similar results have been reported by Kang et al. [40], where authors indicated the higher severity of adverse events after the second vaccination dose. However, only 5% of the study participants sought medical consultation due to severe side effects. The severity of side effects was self-reported in our study and might be associated with perceived severity among study participants. Nevertheless, most of the study participants used only paracetamol, indicating the mild nature of side effects. These findings necessitate the need for further investigations on the severity of side effects based on clinicians‘ observations among patients with chronic illnesses.
It is worth mentioning that only one-third of the study population reported that the COVID-19 vaccines are safe. Although the recommendation of the vaccines to family and friends was high in our study, the widespread concerns over the safety of COVID-19 vaccines among this population were considerable. The data from various countries have indicated that concerns about side effects are the main reason for hesitancy toward COVID-19 vaccines [49,50]. Established evidence has suggested widespread speculation on the safety profile of COVID-19 vaccines among individuals living with comorbidities and endorsed the prioritized measures to tackle vaccine hesitancy and to improve vaccine uptake in this population [15,51,52]. The side effects reported in our study were self-limiting and were primarily linked with the provocation of the immune system by the vaccines. The public sharing of these findings may enhance the confidence of individuals with comorbidities in the safety profile of the COVID-19 vaccines. This may result in the acceleration of the vaccine-coverage process. The side effects after the second dose of COVID-19 vaccines can interfere with booster dose uptake [53]. In this context, educating the population on the safety profile will be of paramount importance. Given the progression of the disease, odds of mortality, and complications linked with COVID-19 infection among chronic-disease patients, the vaccination of this population against COVID-19 holds an instrumental position in mass-vaccination campaigns. In this context, the confidence of this population in the vaccines is a major factor leveraging the vaccination success.

Study Limitations and Strengths

The findings of the current study should be interpreted in light of a few shortcomings. Demerits of convenient sampling, and information bias such as reporting bias and recall bias cannot be disregarded in this study. Since the side effects were self-reported, there is a possibility of incorrect blame, as the study population was also using several medications, and some complaints may have been associated with the use of drugs. The patients with diabetes mellitus, hypertension, hyperlipidemia, and asthma represented most of the study population; therefore, the implications of the findings for patients with other comorbid conditions are limited. The long-term impact of these side effects was not determined in this study, necessitating the need for further investigations in this particular population. Moreover, this study does not provide information on the status of comorbidities, as unstable patients may exaggerate the symptoms after vaccination. Since the safety profile of booster doses of COVID-19 vaccines has been investigated [54], our study does not provide any pharmacovigilance data following the booster dose among chronic-disease patients. Considering the limited number of participants in our analysis, replication and verification of our findings by a larger cohort are warranted. Despite these limitations, our findings are strengthened by a detailed analysis of the side-effect profile of the two doses of COVID-19 vaccines among people having diverse chronic conditions. Since various strong evidence suggests the increased risk of COVID-19, breakthrough infection, and waning vaccine effectiveness among people living with various health conditions [55], optimal vaccination coverage is direly needed in this population. In this context, the findings of the current study will help instill confidence in the COVID-19 vaccines and subsequently increase vaccine coverage in this population. Nevertheless, this study confirms the safety of the COVID-19 vaccines, and its findings can be utilized in creating awareness among this vulnerable population with vaccine hesitancy and ambivalence.

5. Conclusions

This study indicated a high proportion of transient and short-lived side effects of Pfizer and Astra-Zeneca vaccines among individuals with chronic illnesses. Pain at the injection site was a common side effect after the first and second doses. Fatigue and muscle or joint pain were the second-most-common side effects after the first and second dose, respectively. Most of these side effects occurred after 6 h of vaccine administration and lasted for 48 h. The number of comorbid conditions was found to be positively correlated with the side-effect score after the first and second doses. Only a few participants reported that the side effects were severe in nature. Although three-fourths of the study population indicated the recommendation of vaccines to their family members, only one-quarter of vaccinees endorsed COVID-19 vaccines as safe. The side-effects profile reported in this study was comparable with the safety reports of phase 3 clinical trials of these vaccines. It is important to note that the side effects reported in this study require further validation, verification, and replication through active pharmacovigilance or qualitative studies. A larger study with random sampling would likely detect the relationship of side effects between demographics, type and severity of comorbid illness, and the type of vaccine. The results of this study may help in solving the ongoing challenge of vaccine hesitancy in this vulnerable population that is nurtured by widespread concerns over safety profile.

Author Contributions

Conceptualization, T.H.M., Y.H.K., N.H.A. and A.S.A.; formal analysis, M.H.B. and N.T.; funding acquisition, T.H.M. and Y.H.K.; investigation, M.H.B., M.S. and N.T.; methodology, T.H.M., Y.H.K., M.H.B., M.S. and A.I.A.; project administration, T.H.M., Y.H.K., N.H.A. and A.S.A.; resources, M.S. and A.I.A.; software, M.H.B. and M.S.; supervision, T.H.M., N.T., N.H.A., A.I.A. and A.S.A.; validation, N.T., N.H.A. and A.I.A.; visualization, M.S.; writing—original draft, T.H.M., M.H.B. and M.S.; writing—review and editing, Y.H.K., N.T., N.H.A., A.I.A. and A.S.A. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Deanship of Scientific Research at Jouf University under grant number: DSR-2021-01-0335.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Local Committee of Bioethics (LCBE) at Jouf University, KSA (Reference: 05-05-43).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Alsharif, W.; Qurashi, A. Effectiveness of COVID-19 diagnosis and management tools: A review. Radiography 2021, 27, 682–687. [Google Scholar] [CrossRef]
  2. Mallhi, T.H.; Khan, Y.H.; Alzarea, A.I.; Khan, F.U.; Alotaibi, N.H.; Alanazi, A.S.; Butt, M.H.; Alatawi, A.D.; Salman, M.; Alzarea, S.I. Incidence, risk factors and outcomes of acute kidney injury among COVID-19 patients: A systematic review of systematic reviews. Front. Med. 2022, 9, 973030. [Google Scholar] [CrossRef]
  3. Daghriri, T.; Ozmen, O. Quantifying the Effects of Social Distancing on the Spread of COVID-19. Int. J. Environ. Res. Public Health 2021, 18, 5566. [Google Scholar] [CrossRef]
  4. Mallhi, T.H.; Khan, Y.H.; Alotaibi, N.H.; Alzarea, A.I.; Alanazi, A.S.; Qasim, S.; Iqbal, M.S.; Tanveer, N. Drug repurposing for COVID-19: A potential threat of self-medication and controlling measures. Postgrad. Med. J. 2021, 97, 742–743. [Google Scholar] [CrossRef]
  5. Aouissi, H.A.; Kechebar, M.S.A.; Ababsa, M.; Roufayel, R.; Neji, B.; Petrisor, A.-I.; Hamimes, A.; Epelboin, L.; Ohmagari, N. The importance of behavioral and native factors on COVID-19 infection and severity: Insights from a preliminary cross-sectional study. Healthcare 2022, 10, 1341. [Google Scholar] [CrossRef] [PubMed]
  6. Khan, Y.H.; Mallhi, T.H.; Alotaibi, N.H.; Alzarea, A.I.; Alanazi, A.S.; Tanveer, N.; Hashmi, F.K. Threat of COVID-19 vaccine hesitancy in Pakistan: The need for measures to neutralize misleading narratives. Am. J. Trop. Med. Hyg. 2020, 103, 603. [Google Scholar] [CrossRef]
  7. Misbah, S.; Ahmad, A.; Butt, M.H.; Khan, Y.H.; Alotaibi, N.H.; Mallhi, T.H. A systematic analysis of studies on corona virus disease 19 (COVID-19) from viral emergence to treatment. J. Coll. Physicians Surg. Pak. 2020, 30, 9–18. [Google Scholar] [PubMed]
  8. Østergaard, S.D.; Schmidt, M.; Horváth-Puhó, E.; Thomsen, R.W.; Sørensen, H.T. Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: Side-effect or coincidence? Lancet 2021, 397, 1441–1443. [Google Scholar] [CrossRef] [PubMed]
  9. Wan, E.Y.F.; Chui, C.S.L.; Lai, F.T.T.; Chan, E.W.Y.; Li, X.; Yan, V.K.C.; Gao, L.; Yu, Q.; Lam, I.C.H.; Chun, R.K.C. Bell’s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: A case series and nested case-control study. Lancet Infect. Dis. 2022, 22, 64–72. [Google Scholar] [CrossRef] [PubMed]
  10. Salah, H.M.; Mehta, J.L. COVID-19 vaccine and myocarditis. Am. J. Cardiol. 2021, 157, 146–148. [Google Scholar] [CrossRef] [PubMed]
  11. Manning, M.L.; Gerolamo, A.M.; Marino, M.A.; Hanson-Zalot, M.E.; Pogorzelska-Maziarz, M. COVID-19 vaccination readiness among nurse faculty and student nurses. Nurs. Outlook 2021, 69, 565–573. [Google Scholar] [CrossRef]
  12. Riad, A.; Pokorná, A.; Attia, S.; Klugarová, J.; Koščík, M.; Klugar, M. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J. Clin. Med. 2021, 10, 1428. [Google Scholar] [CrossRef]
  13. Lucia, V.C.; Kelekar, A.; Afonso, N.M. COVID-19 vaccine hesitancy among medical students. J. Public Health 2021, 43, 445–449. [Google Scholar] [CrossRef]
  14. Lu, L.; Xiong, W.; Mu, J.; Zhang, Q.; Zhang, H.; Zou, L.; Li, W.; He, L.; Sander, J.W.; Zhou, D. The potential neurological effect of the COVID-19 vaccines: A review. Acta Neurol. Scand. 2021, 144, 3–12. [Google Scholar] [CrossRef]
  15. Lai, F.T.T.; Huang, L.; Chui, C.S.L.; Wan, E.Y.F.; Li, X.; Wong, C.K.H.; Chan, E.W.W.; Ma, T.; Lum, D.H.; Leung, J.C.N. Multimorbidity and adverse events of special interest associated with COVID-19 vaccines in Hong Kong. Nat. Commun. 2022, 13, 411. [Google Scholar] [CrossRef]
  16. Hanlon, P.; Nicholl, B.I.; Jani, B.D.; McQueenie, R.; Lee, D.; Gallacher, K.I.; Mair, F.S. Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: A cross-sectional UK Biobank study. BMJ Open 2018, 8, e018404. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Incalzi, R.A.; Trevisan, C.; Del Signore, S.; Volpato, S.; Fumagalli, S.; Monzani, F.; Bellelli, G.; Gareri, P.; Mossello, E.; Malara, A. Are vaccines against COVID-19 tailored to the most vulnerable people? Vaccine 2021, 39, 2325–2327. [Google Scholar] [CrossRef]
  18. Yi, Z.; Yao, Z.; Xu, D.; Xu, C.; Fang, W.; Guo, Z.; Wang, Y.; Huang, J.; Li, Q.; Zhang, H. Attitudes toward COVID-19 Vaccination: A Survey of Chinese Patients with Rheumatic Diseases. Vaccines 2022, 10, 1604. [Google Scholar] [CrossRef] [PubMed]
  19. Aouissi, H.A.; Belhaouchet, I. What about rheumatic diseases and COVID-19? New Microbes New Infect. 2021, 41, 100846. [Google Scholar] [CrossRef]
  20. Furer, V.; Eviatar, T.; Zisman, D.; Peleg, H.; Paran, D.; Levartovsky, D.; Zisapel, M.; Elalouf, O.; Kaufman, I.; Meidan, R. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: A multicentre study. Ann. Rheum. Dis. 2021, 80, 1330–1338. [Google Scholar] [CrossRef] [PubMed]
  21. Li, Y.K.; Lui, M.P.K.; Yam, L.L.; Cheng, C.S.; Tsang, T.H.T.; Kwok, W.S.; Chung, H.Y. COVID-19 vaccination in patients with rheumatic diseases: Vaccination rates, patient perspectives, and side effects. Immun. Inflamm. Dis. 2022, 10, e589. [Google Scholar] [CrossRef] [PubMed]
  22. Al-Hanawi, M.K.; Ahmad, K.; Haque, R.; Keramat, S.A. Willingness to receive COVID-19 vaccination among adults with chronic diseases in the Kingdom of Saudi Arabia. J. Infect. Public Health 2021, 14, 1489–1496. [Google Scholar] [CrossRef] [PubMed]
  23. Al-Zalfawi, S.M.; Rabbani, S.I.; Asdaq, S.M.B.; Alamri, A.S.; Alsanie, W.F.; Alhomrani, M.; Mohzari, Y.; Alrashed, A.A.; AlRifdah, A.H.; Almagrabe, T. Public knowledge, attitude, and perception towards COVID-19 vaccination in Saudi Arabia. Int. J. Environ. Res. Public Health 2021, 18, 10081. [Google Scholar] [CrossRef]
  24. Alzarea, A.I.; Khan, Y.H.; Alatawi, A.D.; Alanazi, A.S.; Alzarea, S.I.; Butt, M.H.; Almalki, Z.S.; Alahmari, A.K.; Mallhi, T.H. Surveillance of Post-Vaccination Side Effects of COVID-19 Vaccines among Saudi Population: A Real-World Estimation of Safety Profile. Vaccines 2022, 10, 924. [Google Scholar] [CrossRef] [PubMed]
  25. Choi, W.S.; Cheong, H.J. COVID-19 vaccination for people with comorbidities. Infect. Chemother. 2021, 53, 155. [Google Scholar] [CrossRef] [PubMed]
  26. Alemayehu, A.; Demissie, A.; Yusuf, M.; Abdullahi, Y.; Abdulwehab, R.; Oljira, L.; Feleke, D. COVID-19 vaccine side effect: Age and gender disparity in adverse effects following the first dose of AstraZeneca COVID-19 vaccine among the vaccinated population in Eastern Ethiopia: A community-based study. SAGE Open Med. 2022, 10, 20503121221108616. [Google Scholar] [CrossRef]
  27. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting December 10, 2020: FDA Briefing Document, Pfizer-BioNTech COVID-19 Vaccine. 2020. Available online: https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-december-10-2020-meeting-announcement (accessed on 30 October 2022).
  28. Oliver, S.E.; Gargano, J.W.; Marin, M.; Wallace, M.; Curran, K.G.; Chamberland, M.; McClung, N.; Campos-Outcalt, D.; Morgan, R.L.; Mbaeyi, S. The advisory committee on immunization practices’ interim recommendation for use of moderna COVID-19 vaccine—United States, December 2020. Morb. Mortal. Wkly. Rep. 2021, 69, 1653. [Google Scholar] [CrossRef] [PubMed]
  29. Committee for Medicinal Products for Human Use (CHMP). COVID-19 Vaccine AstraZeneca. Product Information as Approved by the CHMP on 29 January 2021, Pending Endorsement by the European Commission. 2021. Available online: https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-astrazeneca-product-information-approved-chmp-29-january-2021-pending-endorsement_en.pdf (accessed on 30 October 2022).
  30. Voysey, M.; Clemens, S.A.C.; Madhi, S.A.; Weckx, L.Y.; Folegatti, P.M.; Aley, P.K.; Angus, B.; Baillie, V.L.; Barnabas, S.L.; Bhorat, Q.E. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021, 397, 99–111. [Google Scholar] [CrossRef] [PubMed]
  31. Vaccines and Related Biological Products Advisory Committee Meeting. FDA Briefing Document. Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. Available online: https://www.fda.gov/media/146217/download (accessed on 30 October 2022).
  32. Ganesan, S.; Al Ketbi, L.M.B.; Al Kaabi, N.; Al Mansoori, M.; Al Maskari, N.N.; Al Shamsi, M.S.; Alderei, A.S.; El Eissaee, H.N.; Al Ketbi, R.M.; Al Shamsi, N.S. Vaccine Side Effects Following COVID-19 Vaccination Among the Residents of the UAE—An Observational Study. Front. Public Health 2022, 10, 876336. [Google Scholar] [CrossRef]
  33. Alghamdi, A.N.; Alotaibi, M.I.; Alqahtani, A.S.; Al Aboud, D.; Abdel-Moneim, A.S. BNT162b2 and ChAdOx1 SARS-CoV-2 post-vaccination side-effects among Saudi vaccinees. Front. Med. 2021, 8, 760047. [Google Scholar] [CrossRef] [PubMed]
  34. Hatmal, M.m.M.; Al-Hatamleh, M.A.I.; Olaimat, A.N.; Mohamud, R.; Fawaz, M.; Kateeb, E.T.; Alkhairy, O.K.; Tayyem, R.; Lounis, M.; Al-Raeei, M. Reported adverse effects and attitudes among Arab populations following COVID-19 vaccination: A large-scale multinational study implementing machine learning tools in predicting post-vaccination adverse effects based on predisposing factors. Vaccines 2022, 10, 366. [Google Scholar] [CrossRef] [PubMed]
  35. Riad, A.; Sağıroğlu, D.; Üstün, B.; Pokorná, A.; Klugarová, J.; Attia, S.; Klugar, M. Prevalence and risk factors of CoronaVac side effects: An independent cross-sectional study among healthcare workers in Turkey. J. Clin. Med. 2021, 10, 2629. [Google Scholar] [CrossRef] [PubMed]
  36. Elnaem, M.H.; Mohd Taufek, N.H.; Ab Rahman, N.S.; Mohd Nazar, N.I.; Zin, C.S.; Nuffer, W.; Turner, C.J. COVID-19 Vaccination Attitudes, Perceptions, and Side Effect Experiences in Malaysia: Do Age, Gender, and Vaccine Type Matter? Vaccines 2021, 9, 1156. [Google Scholar] [CrossRef] [PubMed]
  37. He, Q.; Mao, Q.; Zhang, J.; Bian, L.; Gao, F.; Wang, J.; Xu, M.; Liang, Z. COVID-19 vaccines: Current understanding on immunogenicity, safety, and further considerations. Front. Immunol. 2021, 12, 669339. [Google Scholar] [CrossRef]
  38. Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Marc, G.P.; Moreira, E.D.; Zerbini, C. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [Google Scholar] [CrossRef]
  39. El-Shitany, N.A.; Harakeh, S.; Badr-Eldin, S.M.; Bagher, A.M.; Eid, B.; Almukadi, H.; Alghamdi, B.S.; Alahmadi, A.A.; Hassan, N.A.; Sindi, N. Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: A retrospective cross-sectional study. Int. J. Gen. Med. 2021, 14, 1389. [Google Scholar] [CrossRef]
  40. Kang, Y.M.; Lim, J.; Choe, K.-W.; Lee, K.-D.; Jo, D.H.; Kim, M.J.; Kim, J.M.; Kim, K.N. Reactogenicity after the first and second doses of BNT162b2 mRNA coronavirus disease vaccine: A single-center study. Clin. Exp. Vaccine Res. 2021, 10, 282. [Google Scholar] [CrossRef]
  41. Desalegn, M.; Garoma, G.; Tamrat, H.; Desta, A.; Prakash, A. The prevalence of AstraZeneca COVID-19 vaccine side effects among Nigist Eleni Mohammed memorial comprehensive specialized hospital health workers. Cross sectional survey. PLoS ONE 2022, 17, e0265140. [Google Scholar] [CrossRef]
  42. Omeish, H.; Najadat, A.; Al-Azzam, S.; Tarabin, N.; Abu Hameed, A.; Al-Gallab, N.; Abbas, H.; Rababah, L.; Rabadi, M.; Karasneh, R. Reported COVID-19 vaccines side effects among Jordanian population: A cross sectional study. Hum. Vaccines Immunother. 2022, 18, 1981086. [Google Scholar] [CrossRef]
  43. Rahman, M.; Masum, M.; Ullah, H.; Wajed, S.; Talukder, A. A comprehensive review on COVID-19 vaccines: Development, effectiveness, adverse effects, distribution and challenges. Virusdisease 2022, 33, 1–22. [Google Scholar] [CrossRef]
  44. Amer, F.H.I.; Alzayyat, R.; Alzayyat, N.; Alomran, S.; Wafai, S.; Alabssi, H.; Alsultan, D. Side Effects of COVID-19 Vaccines (Pfizer, AstraZeneca) in Saudi Arabia, Eastern Province. Cureus 2022, 14, e27297. [Google Scholar]
  45. Liu, Q.; Qin, C.; Liu, M.; Liu, J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: A systematic review and meta-analysis. Infect. Dis. Poverty 2021, 10, 132. [Google Scholar] [PubMed]
  46. Al Bahrani, S.; Albarrak, A.; Alghamdi, O.A.; Alghamdi, M.A.; Hakami, F.H.; Al Abaadi, A.K.; Alkhrashi, S.A.; Alghamdi, M.Y.; Almershad, M.M.; Alenazi, M.M. Safety and reactogenicity of the ChAdOx1 (AZD1222) COVID-19 vaccine in Saudi Arabia. Int. J. Infect. Dis. 2021, 110, 359–362. [Google Scholar] [CrossRef] [PubMed]
  47. Ahsan, W.; Syed, N.K.; Alsraeya, A.A.; Alhazmi, H.A.; Najmi, A.; Bratty, M.A.; Javed, S.; Makeen, H.A.; Meraya, A.M.; Albarraq, A.A. Post-vaccination survey for monitoring the side effects associated with COVID-19 vaccines among healthcare professionals of Jazan province, Saudi Arabia. Saudi Med. J. 2021, 42, 1341–1352. [Google Scholar] [CrossRef]
  48. Jensen, A.; Stromme, M.; Moyassari, S.; Chadha, A.S.; Tartaglia, M.C.; Szoeke, C.; Ferretti, M.T. COVID-19 vaccines: Considering sex differences in efficacy and safety. Contemp. Clin. Trials 2022, 115, 106700. [Google Scholar] [CrossRef]
  49. Solís Arce, J.S.; Warren, S.S.; Meriggi, N.F.; Scacco, A.; McMurry, N.; Voors, M.; Syunyaev, G.; Malik, A.A.; Aboutajdine, S.; Adeojo, O. COVID-19 vaccine acceptance and hesitancy in low-and middle-income countries. Nat. Med. 2021, 27, 1385–1394. [Google Scholar] [CrossRef]
  50. Qunaibi, E.; Basheti, I.; Soudy, M.; Sultan, I. Hesitancy of Arab healthcare workers towards COVID-19 vaccination: A large-scale multinational study. Vaccines 2021, 9, 446. [Google Scholar] [CrossRef]
  51. Tsai, R.; Hervey, J.; Hoffman, K.; Wood, J.; Johnson, J.; Deighton, D.; Clermont, D.; Loew, B.; Goldberg, S.L. COVID-19 vaccine hesitancy and acceptance among individuals with cancer, autoimmune diseases, or other serious comorbid conditions: Cross-sectional, internet-based survey. JMIR Public Health Surveill. 2022, 8, e29872. [Google Scholar] [CrossRef]
  52. Alghamdi, A.A.; Aldosari, M.S.; Alsaeed, R.A. Acceptance and barriers of COVID-19 vaccination among people with chronic diseases in Saudi Arabia. J. Infect. Dev. Ctries. 2021, 15, 1646–1652. [Google Scholar] [CrossRef]
  53. Alshahrani, N.Z.; Alsabaani, A.A.; Ridda, I.; Rashid, H.; Alzahrani, F.; Almutairi, T.H.; Alzahrani, B.A.S.; Albeshri, A.S.S. Uptake of COVID-19 Booster Dose among Saudi Arabian Population. Medicina 2022, 58, 972. [Google Scholar] [CrossRef]
  54. Lounis, M.; Aouissi, H.A.; Abdelhadi, S.; Rais, M.A.; Belkessa, S.; Bencherit, D. Short-Term Adverse Effects Following Booster Dose of Inactivated-Virus vs. Adenoviral-Vector COVID-19 Vaccines in Algeria: A Cross-Sectional Study of the General Population. Vaccines 2022, 10, 1781. [Google Scholar] [CrossRef] [PubMed]
  55. Adab, P.; Haroon, S.; O’Hara, M.E.; Jordan, R.E. Comorbidities and COVID-19. BMJ 2022, 377, o1431. [Google Scholar] [CrossRef] [PubMed]
Table
Table 1. Demographics of study participants.
Table 1. Demographics of study participants.
VariablesFrequencyPercentage
Age
18–29 Years2411.8
30–49 Years10551.5
≥50 Years7536.8
Gender
Male9144.6
Female11355.4
Marital status
Single4120.1
Married15877.5
Divorced21.0
Widowed31.5
Comorbidities
Diabetes mellitus8441.2
Hypertension6531.9
Hyperlipidemia6230.4
Asthma5627.5
Anemia31.5
Hypothyroidism125.9
Hyperthyroidism62.9
Gout21.0
Seasonal allergy115.4
Peptic ulcer52.5
Congestive heart failure83.9
Eczema21.0
Comorbidities > 2
Yes3818.6
No16681.4
Allergic to any vaccine
Yes94.4
No19595.6
COVID-19 infection before vaccination
Yes4823.5
No15676.5
COVID-19 infection in family before vaccination
Yes13867.6
No6632.4
COVID-19 infection in acquaintance before vaccination
Yes16178.9
No4321.1
COVID-19 vaccination regime
Astra-Zeneca (two doses)3617.6
Pfizer (two doses)12762.3
Pfizer and Astra-Zeneca4120.1
Type of vaccine during 1st dose
Pfizer16882.4
Astra-Zeneca3617.6
Type of vaccine during 2nd dose
Pfizer12762.3
Astra-Zeneca7737.7
Combination of vaccine
Homologous regime16379.9
Heterologous regime4120.1
COVID-19 infection after vaccination
Yes42.0
No20098.0
Table
Table 2. Frequency of side effects after two doses of COVID-19 vaccines.
Table 2. Frequency of side effects after two doses of COVID-19 vaccines.
First DoseSecond Dose
FrequencyPercentageFrequencyPercentage
Pain at injection site12963.214571.1
Swelling at injection site5125.03014.7
Redness at injection site3517.2209.8
Headache7436.310149.5
Muscle and joint pain7938.712862.7
Fatigue12058.86431.4
Fever9747.59345.6
Stress7838.26833.3
Malaise (feeling sick)4220.6125.9
Chills4120.14723.0
Nausea/vomiting2110.33014.7
Diarrhea2210.83115.2
Cough188.84220.6
Sore throat157.42110.3
Flu-like symptoms157.42110.3
Loss of smell115.42512.3
Loss of taste104.93316.2
Shortness of breath178.35024.5
Menstrual problems21.031.5
Chest pain10.5--
Palpitations10.5--
Hair loss31.531.5
Insomnia104.983.9
Lymph-node swelling21.021.0
Onset of side effects
 Immediately2612.794.4
 Within 6 h9245.15828.4
 Within 6–12 h157.43718.1
 Within 12–24 h2110.32512.3
 After 24 h199.32110.3
 Immediately2612.794.4
Table
Table 3. Relationship of demographics with side-effects score.
Table 3. Relationship of demographics with side-effects score.
VariablesFirst DoseSecond Dose
MeanSDp ValueMeanSDp Values
Age 0.070 0.004
  18–29 Years3.754.235243.632.856
  30–49 Years5.074.0911055.563.648
  ≥50 Years3.714.194754.083.356
Gender <0.001 0.729
  Male3.243.331 4.894.416
  Female5.354.555 4.712.641
Marital status 0.939
  Single4.324.077 4.513.399
  Married4.474.238 4.923.601
  Divorced4.005.657 3.503.536
  Widowed3.003.464 2.671.528
Comorbidities
Diabetes mellitus <0.001 0.249
  No3.163.483 4.553.793
  Yes6.204.453 5.133.123
Hypertension 0.036 0.084
  No1393.99 4.503.431
  Yes655.31 5.423.699
Hyperlipidemia 0.003 0.064
  No3.753.416 4.493.459
  Yes5.945.272 5.483.638
Asthma 0.813 0.730
  No4.363.393 4.743.329
  Yes4.555.806 4.934.062
Anemia 0.916 0.698
  No4.414.192 4.803.555
  Yes4.674.041 4.002.000
Hypothyroidism 0.726 0.704
  No4.444.160 4.773.575
  Yes4.004.671 5.172.949
Hyperthyroidism <0.001 <0.001
  No4.524.200 4.633.469
  Yes1.000.000 10.000.000
Gout 0.658 0.187
  No4.414.199 4.823.538
  Yes5.001.414 1.500.707
Seasonal allergy 0.319 0.955
  No4.344.169 4.793.619
  Yes5.644.388 4.821.537
Peptic ulcer 0.441 0.995
  No4.434.216 4.793.537
  Yes3.802.588 4.803.899
Congestive heart failure 0.080 0.178
  No4.524.207 4.813.605
  Yes1.882.475 4.380.518
Eczema 0.517 0.263
  No4.434.194 4.823.541
  Yes2.502.121 2.001.414
Comorbidities > 2 0.007 <0.001
  Yes6.635.630 6.663.052
  No3.903.605 4.363.508
Allergic to any vaccine 0.279 0.766
  Yes5.895.302 4.442.242
  No4.344.126 4.813.587
COVID-19 infection before vaccination 0.141 0.117
  Yes3.753.219 4.543.246
  No4.624.423 5.604.286
COVID-19 infection in family before vaccination 0.012 0.009
  Yes1383.80 1385.21
  No665.68 663.91
COVID-19 infection in acquaintance before vaccination 0.046 0.003
  Yes1613.96 1614.76
  No436.09 434.91
COVID-19 vaccination regime 0.005 0.593
  Astra-Zeneca (two doses)6.443.308 5.333.033
  Pfizer (two doses)3.964.571 4.693.802
  Pfizer and Astra-Zeneca4.022.962 4.613.089
Type of vaccine during 1st dose 0.001 -
  Pfizer3.984.227 --
  Astra-Zeneca6.443.308 --
Type of vaccine during 2nd dose 0.047
  Pfizer-- 3.964.571
  Astra-Zeneca-- 5.163.337
Combination of vaccine 0.717
  Homologous regime-- 4.833.647
  Heterologous regime-- 4.613.089
The bold values represent statistical significance.
Table
Table 4. Distribution of common and moderately common side effects across demographic features after 1st dose of COVID-19 vaccine.
Table 4. Distribution of common and moderately common side effects across demographic features after 1st dose of COVID-19 vaccine.
VariableSub-variableHeadacheInjection-Site PainFatigueBone-Joint PainStressFever
NoYesNoYesNoYesNoYesNoYesNoYes
%%%%%%%%%%%%
GenderMale52.031.05.040.057.035.050.035.04.042.052.036.0
Female47.068.04.059.042.064.049.064.05.057.047.063.0
p-value0.003 *0.10.003 *0.036 *0.60.020 *
Age18–29 Years13.09.013.010.015.09.01.011.011.012.01.08.0
30–49 years5.054.054.049.035.062.04.05.041.067.043.059.0
>50 Years36.036.03.039.048.028.04.031.047.019.041.03.0
p-value0.70.50.001 *0.4<0.001 *0.1
Marital statusSingle22.016.02.017.020.02.019.021.020.019.019.020.0
Married73.083.074.079.076.078.078.075.07.078.077.077.0
Divorced1.0 1.00.01.00.00.01.00.01.00.0
Widowed2.0 2.02.00.01.01.01.01.01.0
p-value0.20.40.81.01.01.0
Allergic to vaccineNo95.095.09.095.096.09.095.096.09.094.097.093.0
Yes4.04.0 4.03.0 4.03.0 5.02.06.0
P-value0.90.80.60.70.70.2
COVID-19-infectedNo70.086.081.073.078.07.077.074.075.078.07.082.0
Yes29.013.018.026.021.02.022.025.024.021.02.017.0
P-value0.011 *0.20.60.60.60.1
Family member infected with COVID-19No25.044.029.034.03.033.025.04.030.035.029.035.0
Yes74.055.070.065.06.066.074.05.069.064.070.064.0
P-value0.005 *0.50.70.010 *0.40.4
Friends infected with COVID-19No21.020.02.017.020.021.020.021.02.017.01.027.0
Yes78.079.07.082.079.078.079.078.07.082.08.072.0
p-value0.80.10.80.90.40.024 *
COVID-19 infection after vaccinationsNo97.098.098.097.098.097.010.094.099.096.098.097.0
Yes2.01.01.02.01.02.0 5.00.03.01.02.0
p-value0.60.60.50.011 *0.10.9
Vaccine typeAZ two doses11.028.01.018.09.023.09.030.018.016.0 37.0
Pfizer two doses67.052.06.061.071.055.070.049.066.055.078.044.0
Pfizer and AZ20.018.02.020.01.020.02.020.015.028.021.018.0
p-value0.009 *0.90.025 *<0.001 *0.1<0.001 *
* Statistical significance.
Table
Table 5. Distribution of common and moderately common side effects across demographic features after 2nd dose of COVID-19 vaccine.
Table 5. Distribution of common and moderately common side effects across demographic features after 2nd dose of COVID-19 vaccine.
VariableSub-VariableHeadacheInjection-Site PainFatigueBone-Joint PainStressFever
NoYesNoYesNoYesNoYesNoYesNoYes
GenderMale50.538.669.534.546.143.848.635.941.95045.943
Female49.561.430.565.553.956.351.464.158.15054.157
p-value0.088<0.001 *0.0920.7490.2730.674
Age18-29 Years14.68.9016.615.89.415.73.112.510.317.15.4
30–49 Years51.551.530.56043.456.351.451.649.355.945.958.1
>50 Years3439.669.523.440.834.432.945.338.233.836.936.6
p-value0.402<0.001 *0.021 *0.1550.6660.025 *
Marital statusSingle24.315.8028.323.71822.115.620.619.124.315.1
Married73.881.298.36972.480.574.384.476.579.472.183.9
Divorced1101.41.30.81.401.500.91.1
Widowed121.71.42.60.82.101.51.52.70
p-value0.472<0.001 *0.2850.4880.7770.133
Allergic to vaccineNo93.29898.394.597.494.59596.994.997.196.494.6
Yes6.821.75.52.65.553.15.12.93.65.4
p-value0.0940.2280.5450.340.470.539
COVID-19-infectedNo74.878.274.677.272.478.981.465.610029.47380.6
Yes25.221.825.422.827.621.118.634.4070.62719.4
p-value0.560.6840.014 *0.287<0.001 *0.198
Family member infected with COVID-19No3430.73929.748.722.733.629.746.34.425.240.9
Yes6669.36170.351.377.366.470.353.795.674.859.1
p-value0.6160.1970.582<0.001 *<0.001 *0.017 *
Friends infected with COVID-19No22.319.82220.72518.816.431.327.28.816.226.9
Yes77.780.27879.37581.383.668.872.891.283.873.1
p-value0.6580.8310.016 *0.290.002 *0.063
COVID-19 infection after vaccinationsNo98.19810097.298.797.797.998.499.395.699.196.8
Yes1.9202.81.32.32.11.60.74.40.93.2
p-value0.9840.1980.7810.6090.0740.233
Vaccine typeAZ two doses17.517.815.318.615.818.817.917.222.87.4038.7
Pfizer two doses55.369.355.964.873.755.56067.258.170.675.746.2
Pfizer and AZ27.212.928.816.610.525.822.115.619.122.124.315.1
p-value0.033 *0.1390.5210.016 *0.024 *<0.001 *
* Statistical significance.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Mallhi, T.H.; Khan, Y.H.; Butt, M.H.; Salman, M.; Tanveer, N.; Alotaibi, N.H.; Alzarea, A.I.; Alanazi, A.S. Surveillance of Side Effects after Two Doses of COVID-19 Vaccines among Patients with Comorbid Conditions: A Sub-Cohort Analysis from Saudi Arabia. Medicina 2022, 58, 1799. https://doi.org/10.3390/medicina58121799

AMA Style

Mallhi TH, Khan YH, Butt MH, Salman M, Tanveer N, Alotaibi NH, Alzarea AI, Alanazi AS. Surveillance of Side Effects after Two Doses of COVID-19 Vaccines among Patients with Comorbid Conditions: A Sub-Cohort Analysis from Saudi Arabia. Medicina. 2022; 58(12):1799. https://doi.org/10.3390/medicina58121799

Chicago/Turabian Style

Mallhi, Tauqeer Hussain, Yusra Habib Khan, Muhammad Hammad Butt, Muhammad Salman, Nida Tanveer, Nasser Hadal Alotaibi, Abdulaziz Ibrahim Alzarea, and Abdullah Salah Alanazi. 2022. "Surveillance of Side Effects after Two Doses of COVID-19 Vaccines among Patients with Comorbid Conditions: A Sub-Cohort Analysis from Saudi Arabia" Medicina 58, no. 12: 1799. https://doi.org/10.3390/medicina58121799

Article Metrics

Back to TopTop